Tarsus Pharmaceuticals Q4 2023 Earnings Report $46.52 -0.40 (-0.85%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Tarsus Pharmaceuticals EPS ResultsActual EPS-$1.31Consensus EPS -$1.37Beat/MissBeat by +$0.06One Year Ago EPS-$0.49Tarsus Pharmaceuticals Revenue ResultsActual Revenue$13.08 millionExpected Revenue$4.63 millionBeat/MissBeat by +$8.45 millionYoY Revenue GrowthN/ATarsus Pharmaceuticals Announcement DetailsQuarterQ4 2023Date2/27/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseTARS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Tarsus Pharmaceuticals Earnings HeadlinesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by BrokeragesJanuary 18 at 3:12 AM | americanbankingnews.comTarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular RosaceaJanuary 16 at 9:27 AM | markets.businessinsider.comMore AI patents than Nvidia, OpenAI and Tesla combinedIf you own a smartphone, there’s a good chance you’re already benefiting from its technology—because it’s on hundreds of millions of devices worldwide. But you don’t see it’s logo on the outside of the tech gadgets you buy… That’s because it’s on the inside, making up the app’s and components that run your smartphone, your computer, and everything else… January 18, 2025 | The Oxford Club (Ad)Tarsus Pharmaceuticals (TARS) Receives a Buy from BarclaysJanuary 16 at 9:27 AM | markets.businessinsider.comTarsus Pharmaceuticals provides 2025 updateJanuary 14, 2025 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)January 14, 2025 | markets.businessinsider.comSee More Tarsus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tarsus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your email. Email Address About Tarsus PharmaceuticalsTarsus Pharmaceuticals (NASDAQ:TARS), a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.View Tarsus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
